# Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

> **NCT04629833** · PHASE3 · RECRUITING · sponsor: **medac GmbH** · enrollment: 210 (estimated)

## Conditions studied

- Steroid-refractory Acute Graft-versus-host Disease

## Interventions

- **BIOLOGICAL:** MC0518
- **BIOLOGICAL:** BAT

## Key facts

- **NCT ID:** NCT04629833
- **Lead sponsor:** medac GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-16
- **Primary completion:** 2027-08
- **Final completion:** 2030-08
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04629833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04629833, "Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT04629833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*